TITLE

Pharmacokinetics of a Fixed-Dose Combination of Mitiglinide and Metformin versus Concurrent Administration of Individual Formulations in Healthy Subjects

AUTHOR(S)
Jin Ah Jung; Jung-Ryul Kim; Suk-Ran Kim; Tae-Eun Kim; Soo-Youn Lee; Jae-Wook Ko; Wooseong Huh
PUB. DATE
December 2012
SOURCE
Clinical Drug Investigation;2012, Vol. 32 Issue 12, p799
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background In the treatment of diabetes mellitus, combined drugs with different mechanisms of action can be effective when adequate glycaemic control is difficult with monotherapy. A fixed-dose combination (FDC) tablet of mitiglinide and metformin has been developed as a second-line treatment for type 2 diabetes. Objectives The objective of this study was to compare the pharmacokinetics and safety of a FDC and a free combination of mitiglinide and metformin in healthy male subjects. Methods A randomized, open-label, two-period, two-treatment, single-dose, crossover study was conducted in 24 healthy Korean male subjects. In one period, a FDC tablet of mitiglinide and metformin (10 mg/500 mg) was administered, and in the other period, corresponding doses of individual formulations were administered. Results Twenty-four subjects were enrolled and 19 subjects completed the study. The geometric mean ratios (90 % confidence interval) of the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUClast) were 0.9694 (0.8120, 1.1573) and 0.8951 (0.8440, 0.9494) for mitiglinide, and 1.0235 (0.9373, 1.1057) and 1.0542 (0.9697, 1.1460) for metformin, which were within the bioequivalence range. Among the 23 subjects who received study drugs, 15 subjects experienced 34 adverse events (AEs). The most frequently reported AEs were feeling hot and compensatory sweating. There were no serious AEs and no significant differences in the incidence of AEs between the two treatments. Conclusion A FDC tablet of mitiglinide and metformin was generally well tolerated in healthy male subjects. Administration of a FDC tablet and concomitant administration of individual formulations did not show significantly different pharmacokinetic profiles.
ACCESSION #
84507980

 

Related Articles

  • The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily. MENEGHINI, LUIGI; ATKIN, STEPHEN L.; GOUGH, STEPHEN C. L.; RAZ, ITAMAR; BLONDE, LAWRENCE; SHESTAKOVA, MARINA; BAIN, STEPHEN; JOHANSEN, THUE; BEGTRUP, KAMILLA; BIRKELAND, KÅRE I. // Diabetes Care;Apr20123, Vol. 36 Issue 4, p858 

    OBJECTIVE--The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec (IDeg), an ultra-long-acting basal insulin....

  • Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus. Kolodka, Tadeusz; Charles, Matthew L.; Raghavan, Arvind; Radichev, Ilian A.; Amatya, Christina; Ellefson, Jacob; Savinov, Alexei Y.; Nag, Abhijeet; Williams, Mark S.; Robbins, Mark S. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Modulation of the kallikrein-kinin system (KKS) has been shown to have beneficial effects on glucose homeostasis and several other physiological responses relevant to the progression of type 2 diabetes mellitus (T2D). The importance of bradykinin and its receptors in mediating these responses is...

  • Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs. HIRSHBERG, BOAZ; RAZ, ITAMAR // Diabetes Care;May2011 Supplement 2, Vol. 34, pS101 

    The article examines the drivers for the regulations of the U.S. Food and Drug Administration related to cardiovascular (CV) safety of type 2 diabetes treatments as well as its impact on the development of novel anti-diabetes drugs. According to results of outcome studies, a surrogate biomarker...

  • Correlates of Treatment Patterns Among Youth With Type 2 Diabetes. Badaru, Angela; Klingensmith, Georgeanna J.; Dabelea, Dana; Mayer-Davis, Elizabeth J.; Dolan, Lawrence; Lawrence, Jean M.; Marcovina, Santica; Beavers, Daniel; Rodriguez, Beatriz L.; Imperatore, Giuseppina; Pihoker, Catherine // Diabetes Care;Jan2014, Vol. 37 Issue 1, p64 

    The article presents a study which described the treatment regimens in young people with type 2 diabetes, as well as examined the links between regimens, demographic and clinical characteristics, and glycemic control. Among the treatment regimen are lifestyle alone, metformin monotherapy, and...

  • Invokamet and Xigduo XR--two new combinations for type 2 diabetes.  // JAMA: Journal of the American Medical Association;2/10/2015, Vol. 313 Issue 6, p620 

    A reprint of the article "Invokamet and Xigduo XR - Two New Combinations for Type 2 Diabetes," which appeared in the December 8, 2014 issue of "The Medical Letter on Drugs and Therapeutics". It discusses the fixed-dose combinatinos of metformin with either Invokamet or Xigduo XR for treating...

  • Glycemic Therapy for Type 2 Diabetes: Choices Expand, Data Lag Behind. Fradkin, Judith E.; Rodgers, Griffin P. // Annals of Internal Medicine;2/21/2017, Vol. 166 Issue 4, p309 

    The authors discuss the clinical guideline from the American College of Physicians (ACP) on the oral pharmacologic treatment of type 2 diabetes mellitus (T2DM). Topics include the basis of the guideline, basis of the recommendation of the ACP on metformin as initial drug therapy for T2DM, and...

  • United States : U.S. FDA Approves INVOKAMET (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes.  // TendersInfo News;8/9/2014, p1 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on INVOKAMET, a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet developed by pharmaceutical company Janssen Pharmaceuticals Inc. It mentions that the drug is a treatment...

  • Metformin.  // AHFS Consumer Medication Information;Jun2020, p1 

    Metformin is used alone or with other medications, including insulin, to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). Metformin helps to control the amount of glucose (sugar) in your blood. It...

  • Bioequivalence Study of Metformin HCl XR Caplet Formulations in Healthy Indonesian Volunteers. Purnasari, Santi; Hayun, Hayun; Dianpratami, Krisnasari; Wulandari, Mahi; Rahmawati, Rina; Chany, Fadlina; Radite, Radite // Journal of Bioequivalence & Bioavailability;2011, Vol. 3 Issue 1, p16 

    Aim: Determination of the bioequivalence of two metformin HCl (750 mg) caplet formulations (Glucophage XR® from Bristol-Myres Squibb Company, Indonesia as a reference formulation and Glumin XR® from Ferron Par Pharmaceutical, Indonesia as a test formulation). Material and method: The study...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics